Cell Death Dis: The small molecular compound AH057 and SGI-1027 inhibit the development of cervical cancer cells.

Cervical cancer (CC) is the third most common gynaecological cancer, characterized by high morbidity and mortality among women worldwide.
more than 85 per cent of CC morbidity and mortality occur mainly in developing countries, which are still under-diagnosed.
although significant progress has been made in the treatment of CC through treatments such as surgery, radiotherapy and chemotherapy, the prognostication of patients with advanced CC is still poor due to the recurrence and metastasis of tumors.
, it is urgent to develop more effective and specific CC treatment strategies.
the study identified a variety of candidates for new JAK inhibitors by simulating the screening of the SPECS database, and assessed the anti-tumor effects of these candidate drugs, especially on CC cell line.
AH057 is recognized as the best JAK inhibitor, which can effectively block the JAK/STAT signaling path through direct inhibition of JAK1/2 kinase activity, which eventually leads to the inhibition of cell proliferation and invasion, the increase of apoptosis, the stagnation of cell cycles and the suppression of tumor development.
researchers further screened the Selleck Chemical Library for SGI-1027, a compound with the highest synergy with AH057.
AH057 and SGI-1027 can be used in collaboration to inhibit the proliferation of CC cells by acting on a set of downstream effect molecules controlled by JAK1/2 and DNMT1.
in summary, the above results show that the clinical evidence of dual target JAK1/2 and DNMT1 for cervical cancer treatment also supports the clinical analysis of the efficacy and safety of drug-combined treatment of CC and other malignant tumor patients.
.